SUMMARY
We compared the number/percentages of naive and memory CD4 T-cell counts (moderately advanced). We limited our analysis to patients who become undetectable after 6 months of HAART and maintained <50 copies/ml during the follow-up period.
METHODS

Study design and patients:
This prospective, four-year longitudinal study was conducted at the University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia between the December of 1998. and November of 2002. We enrolled 30 treatment-naive HIV-1 infected adults. HIV-patients were treated with a combination of zidovudine or stavudine, lamivudine and indinavir at standard doses. Included in this analysis were 24 patients who become undetectable (less than 50 copies of HIV-1 RNA per ml of plasma) at 6 months and stayed so thereafter.
Immunological (flow cytometry) and virological analysis (quantitative RT-PCR for HIV-1 RNA) were done before and after 1, 3, 6, 12, 24 and 48 months of treatment. Plasma samples for HIV-1 RNA quantification and peripheral blood samples for flow cytometry were collected as a part of routine diagnostic follow-up.
The study also included 32 apparently healthy controls. Informed consent was obtained from all patients and healthy controls. The study excluded children (< 17 years of age) and pregnant women. The study was approved by the Ethics committee of the Hospital.
Viral load
The quantification of HIV-1 RNA in the plasma of HIV-1-infected persons was performed by using Cobas Amplicor TM HIV-1 monitor Test, version 1.5, 6 UltraSensitive specimen preparation (Roche Diagnostic Systems, Inc., Branchburg, New Jersey, USA) with lower limit of detection of 50 copies of HIV-1 RNA/ml.
Flow cytometry
To assess the quantity of T-cell immune reconstitution, we compared several lymphocyte subpopulations in HIV-1-infected patients before and during treatment to Beckman Coulter, Inc., FL, USA) as recommended [14] .
Peripheral blood samples were prepared for flow cytometry by using a whole blood non-wash method on Multi-Q-Prep System with ImmunoPrep Reagent System (Beckman Coulter, Inc., FL, USA). The samples were analysed on Epics XL-MCL flow cytometer (Beckman Coulter, Inc., FL, USA).
Statistical analysis
The changes in immunological parameters from baseline throughout the follow-up period were analysed by Wilcoxon signed rank test (p<0.05 was considered significant). The comparison between two independent groups was done by MannWhitney test. All reported p-values are two-sided and exact. A generalized additive model was fit and trajectories of T-cell counts were described by drawing a smooth curve using robust local regression [15] . Statistical analysis was performed with SAS software version 8.2 [16] and StatXact release 5.0.3. (Cytel Software Corporation, USA). The loess option of PROC GAM was used to plot T-cells over time [16] . 8 
RESULTS:
Patients
Out of 30 patients enrolled, 24 met the inclusion criteria related to the undetectable viral load within 6 months of starting their first HAART regimen and completed all follow-ups. Pre-treatment viremia in 24 patients included in this analysis was 5.3 log 10 copies of HIV-1 RNA/ml (range 3.4-6.7 log 10 copies of HIV-1 RNA/ml). After 3 months of HAART, plasma viremia was undetectable in 14 patients. Ten out of 24 patients had detectable plasma viremia after 3 months of treatment (median 3.6 log 10 copies of HIV-1 RNA/ml, range 3.0-4.8 log 10 copies of HIV-1 RNA/ml) but subsequently achieved undetectable plasma viremia after 6 months of HAART.
The patients were divided into two groups, based on their initial CD4 Table 2 ). The changes in CD4+ T-cell counts in moderately advanced patients were more gradual compared with advanced patients.
Advanced HIV-infected patients gained more CD4 Figure 1 ).
Naive CD4 + T-cells
Percentages of naive CD4 + T-cells increased in advanced patients increased from baseline (median 0.9%, IQR 0-15%) to a median of 40.2% (IQR 37.0-45.6%) after 48 months of treatment (Table 3 ). There was an early and statistically significant increase in naive CD4 In less advanced patients, naive CD4 + T-cells increased from a median 32.6%
(IQR 21.2-48.7%) at baseline to 50.6% (IQR 38.9-56.9%) after 48 months of HAART ( Figure 2 ).
Memory CD45RO + T-cells
Suppressive HAART enabled an increase in memory CD4 at the end of follow-up (Table 3) . Similarly to advanced patients, an early and statistically significant increase in memory CD4 months (6.7 vs 1.6%), 12 months (6.9 vs 2.4%), 24 months (7.5 vs 3.1%) and 48 months (11.3 vs 6.8%) (p=0.002; p=0.013; p<0.001; p=0.004; p=0.001; p=0.015, respectively, Figure 3 ). (Table 2. ).
CD8 + T-cells
Other lymphocyte subpopulations
There was no difference in the kinetics of CD38 
